Kyverna Therapeutics' IND application for MS therapy receives clearance
Kyverna Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for KYV-101
Page 4 - Peter Maag News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Maag. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Maag Today - Breaking & Trending Today
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for...
Source: prnewswire.com
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it...
Source: lelezard.com
Kyverna's CAR T-Cell Therapy Expands Autoimmune Investigations Into Myasthenia Gravis
The therapy is already being evaluated in patients with lupus nephritis and diffuse cutaneous systemic sclerosis.
Source: ajmc.com
Haivision, Grabyo Launch Fully Integrated Solution for Live Multi-Camera Cloud Production
The offering uses Haivision’s video contribution solutions to stream synchronized ultra-low latency video to the Grabyo cloud production platform
Source: tvtechnology.com